keyword
MENU ▼
Read by QxMD icon Read
search

Cidp

keyword
https://www.readbyqxmd.com/read/29145880/anti-nf155-chronic-inflammatory-demyelinating-polyradiculoneuropathy-strongly-associates-to-hla-drb15
#1
Laura Martinez-Martinez, Ma Cinta Lleixà, Gemma Boera-Carnicero, Andrea Cortese, Jérôme Devaux, Ana Siles, Yusuf Rajabally, Alicia Martinez-Piñeiro, Alejandra Carvajal, Julio Pardo, Emilien Delmont, Shahram Attarian, Jordi Diaz-Manera, Ilaria Callegari, Enrico Marchioni, Diego Franciotta, Luana Benedetti, Guiseppe Lauria, Oscar de la Calle Martin, Cándido Juárez, Isabel Illa, Luis Querol
BACKGROUND: The aim of the research is to study the human leukocyte antigen (HLA) class II allele frequencies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) associated with anti-neurofascin 155 (NF155) antibodies. METHODS: Thirteen anti-NF155+ and 35 anti-NF155 negative (anti-NF155neg) CIDP patients were included in a case-control study. The frequencies of the DRB1 HLA allele were analyzed in all patients while DQ frequencies were only studied in patients sharing the DRB1*15 allele...
November 16, 2017: Journal of Neuroinflammation
https://www.readbyqxmd.com/read/29137897/elevated-serum-levels-of-endothelin-1-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy
#2
Chun-Wei Chang, Hsiu-Chuan Wu, Rong-Kuo Lyu, Yen-Shi Lo, Chiung-Mei Chen, Long-Sun Ro, Hong-Shiu Chang, Ching-Chang Huang, Ming-Feng Liao, Yih-Ru Wu, Hong-Chou Kuo, Chun-Che Chu, Yi-Ching Weng, Pei-Tsi Wei, Ai-Lun Lo, Kuo-Hsuan Chang
INTRODUCTION: A Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired, or non-hereditary, chronic demyelinating neuropathy. Currently, there is no reliable molecular biomarker that can identify CIDP patients as well as monitor disease severity. MATERIAL AND METHODS: We measured serum levels of endothelin-1 (ET-1), a factors involved in vasoconstrictive, inflammatory and nerve regenerative processes, in the serum of 20 CIDP, 21 acute inflammatory demyelinating polyneuropathy (AIDP), 37 multiple sclerosis (MS), and 10 Alzheimer's disease (AD) patients, as well as 26 healthy control (HC) subjects...
November 11, 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/29130507/neurofascin-155-igg4-neuropathy-pathophysiological-insights-spectrum-of-clinical-severity-and-response-to-treatment
#3
Nidhi Garg, Susanna B Park, Con Yiannikas, Steve Vucic, James Howells, Yu-Ichi Noto, Emily K Mathey, John D Pollard, Matthew C Kiernan
INTRODUCTION: Sensorimotor neuropathy associated with IgG4 antibodies to neurofascin-155 (NF155) was recently described. The clinical phenotype is typically associated with young onset, distal weakness and in some cases, tremor. METHODS: From a consecutive cohort of 55 patients diagnosed with chronic inflammatory demyelinating polyneuropathy, screening for anti-NF155 antibodies was undertaken. Patients underwent clinical assessment, diagnostic neurophysiology, including peripheral axonal excitability studies and nerve ultrasound...
November 11, 2017: Muscle & Nerve
https://www.readbyqxmd.com/read/29125079/-relapse-of-chronic-inflammatory-demyelinating-polyneuropathy-following-treatment-with-zoledronic-acid
#4
M Loef, E C T Geijteman, K J Beelen, M Bornebroek, D H Schweitzer
BACKGROUND: Zoledronic acid is a nitrogen-containing bisphosphonate that is frequently used in the treatment of osteoporosis. Many patients experience a so-called acute-phase reaction during initial treatment; this is characterized by flu-like symptoms and fever. CASE DESCRIPTION: We describe a 61-year-old woman who suffered from chronic inflammatory demyelinating polyneuropathy (CIDP), and who was started on intravenous zoledronic acid treatment as adjuvant therapy for breast cancer...
2017: Nederlands Tijdschrift Voor Geneeskunde
https://www.readbyqxmd.com/read/29122523/subcutaneous-immunoglobulin-for-maintenance-treatment-in-chronic-inflammatory-demyelinating-polyneuropathy-path-a-randomised-double-blind-placebo-controlled-phase-3-trial
#5
Ivo N van Schaik, Vera Bril, Nan van Geloven, Hans-Peter Hartung, Richard A Lewis, Gen Sobue, John-Philip Lawo, Michaela Praus, Orell Mielke, Billie L Durn, David R Cornblath, Ingemar S J Merkies
BACKGROUND: Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates in patients given SCIg versus placebo. METHODS: Between March 12, 2012, and Sept 20, 2016, we studied patients from 69 neuromuscular centres in North America, Europe, Israel, Australia, and Japan...
November 6, 2017: Lancet Neurology
https://www.readbyqxmd.com/read/29119642/protocol-of-a-dose-response-trial-of-iv-immunoglobulin-in-chronic-inflammatory-demyelinating-polyradiculoneuropathy-drip-study
#6
K Kuitwaard, W J R Fokkink, E Brusse, A F J E Vrancken, F Eftimov, N C Notermans, A J van der Kooi, I S J Merkies, B C Jacobs, P A van Doorn
High peak levels of serum IgG may not be needed for maintenance treatment of CIDP with IVIg. More frequent dosing of IVIg leads to more stable IgG levels and higher trough levels which may be related with improved clinical efficacy. More frequent lower dosing leads to lower peak levels and may induce less systemic side-effects. The DRIP study is a double-blind randomized controlled cross-over intervention study. CIDP patients ≥ 18 years old, proven IVIg dependent and receiving an individually established but stable maintenance dose and interval of IVIg (Kiovig) can be included...
November 9, 2017: Journal of the Peripheral Nervous System: JPNS
https://www.readbyqxmd.com/read/29092099/maintenance-iv-immunoglobulin-treatment-in-chronic-inflammatory-demyelinating-polyradiculoneuropathy
#7
REVIEW
K Kuitwaard, W J R Fokkink, E Brusse, A F J E Vrancken, F Eftimov, N C Notermans, A J van der Kooi, I S J Merkies, B C Jacobs, P A van Doorn
CIDP patients treated with intravenous immunoglobulin (IVIg) usually start with a standard dosage of 2 g/kg body weight. Only a minority of patients have a sustained improvement, and most require ongoing maintenance treatment. Preferred IVIg regimens however vary considerably between doctors and at present it is unknown which is optimal. Since there are also large differences in IVIg dosage and interval requirements between patients, optimal IVIg maintenance treatment of CIDP is even more complex. The lack of evidence based guidelines on how IVIg maintenance treatment should be administered may potentially lead to under- or overtreatment of this expensive therapy...
November 1, 2017: Journal of the Peripheral Nervous System: JPNS
https://www.readbyqxmd.com/read/29089585/antibodies-against-peripheral-nerve-antigens-in-chronic-inflammatory-demyelinating-polyradiculoneuropathy
#8
Luis Querol, Ana M Siles, Roser Alba-Rovira, Agustín Jáuregui, Jérôme Devaux, Catherine Faivre-Sarrailh, Josefa Araque, Ricard Rojas-Garcia, Jordi Diaz-Manera, Elena Cortés-Vicente, Gisela Nogales-Gadea, Miquel Navas-Madroñal, Eduard Gallardo, Isabel Illa
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous disease in which diverse autoantibodies have been described but systematic screening has never been performed. Detection of CIDP-specific antibodies may be clinically useful. We developed a screening protocol to uncover novel reactivities in CIDP. Sixty-five CIDP patients and 28 controls were included in our study. Three patients (4.6%) had antibodies against neurofascin 155, four (6.2%) against contactin-1 and one (1.5%) against the contactin-1/contactin-associated protein-1 complex...
October 31, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29075571/quantitative-muscle-ultrasound-is-useful-for-evaluating-secondary-axonal-degeneration-in-chronic-inflammatory-demyelinating-polyneuropathy
#9
Keiichi Hokkoku, Kiyoshi Matsukura, Yudai Uchida, Midori Kuwabara, Yuichi Furukawa, Hiroshi Tsukamoto, Yuki Hatanaka, Masahiro Sonoo
INTRODUCTION: In chronic inflammatory demyelinating polyneuropathy (CIDP), exclusion of secondary axonal degeneration is challenging with conventional methods such as nerve conduction study (NCS), needle electromyography, and nerve biopsy. Increased echo intensity (EI) and decreased muscle thickness (MT) identified on muscle ultrasound (MUS) examination represent muscle denervation due to axonal degeneration in neurogenic disorders, suggesting MUS as a new tool to detect secondary axonal degeneration in patients with CIDP...
October 2017: Brain and Behavior
https://www.readbyqxmd.com/read/29073825/myasthenia-gravis-and-chronic-inflammatory-demyelinating-polyneuropathy-in-the-same-patient-a-case-report
#10
Weiwei Quan, Junhui Xia, Qiuling Tong, Jie Lin, Xiaolu Zheng, Xuezhi Yang, Dewei Xie, Yiyun Weng, Xu Zhang
We reported a misdiagnosed case of a 66-year-old man who concomitantly developed chronic inflammatory demyelinating polyneuropathy (CIDP) and myasthenia gravis (MG), which was rarely reported. This man presented with chronic progressive sensory symptoms, flaccid tetraparesis, areflexia and protein-cell dissociation of cerebrospinal fluid. Nerve conduction study was indicative of demyelinating neuropathy. He was suspected as CIDP and treated with high-dose glucocorticoids. However, his condition worsened. Four months later, he was admitted and was diagnosed as combination of CIDP and MG...
October 27, 2017: International Journal of Neuroscience
https://www.readbyqxmd.com/read/29065233/-chronic-inflammatory-demyelinating-polyradiculoneuropathy-clinical-aspects-and-new-animal-models-of-auto-immunity-to-nodal-components
#11
Isabel Illa
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic and treatable disorder of the peripheral nerves with clinical and immunological heterogeneity.
October 24, 2017: Journal of the Peripheral Nervous System: JPNS
https://www.readbyqxmd.com/read/29053880/electrodiagnostic-errors-contribute-to-cidp-misdiagnosis
#12
Jeffrey A Allen, John Ney, Richard A Lewis
INTRODUCTION: Documentation of peripheral nerve demyelination is an important part of the CIDP diagnostic process. METHODS: We performed a retrospective analysis of patients referred with a diagnosis of CIDP who were found to have a different condition. Electrodiagnostic study data and interpretations performed at the time of the initial diagnosis were compared to those obtained during the re-evaluation. RESULTS: Thirty-nine of 86 patients were found to not have CIDP...
October 20, 2017: Muscle & Nerve
https://www.readbyqxmd.com/read/29043889/unconventional-treatments-for-chronic-inflammatory-demyelinating-polyneuropathy
#13
Yusuf A Rajabally
This article focuses on the unconventional treatments used in chronic inflammatory demyelinating polyneuropathy (CIDP). First line, evidence-based treatments for CIDP include corticosteroids, immunoglobulins and plasma exchanges. Several unproven treatments are however given in treatment-refractory disease or to reduce requirements in validated therapies for reasons of side effects/practical delivery/cost. Despite methodological issues, IFN-α, azathioprine and methotrexate have not been shown to be useful in randomized controlled trials...
October 18, 2017: Neurodegenerative Disease Management
https://www.readbyqxmd.com/read/29034435/advances-in-the-treatment-of-paraproteinemic-neuropathy
#14
REVIEW
Eduardo Nobile-Orazio, Mariangela Bianco, Andrea Nozza
Purpose of review Several advances have been made on the pathogenesis and therapy of neuropathies associated with paraproteinemia (monoclonal gammopathy). It is important for the neurologist to understand the pathogenetic relevance of this association especially when the hematological disease does not require per se any therapy. Recent findings Treatment of the neuropathy in patients with malignant paraproteinemia is mainly addressed by the hematologist while the neurologist is mainly involved in the initial diagnosis and in deciding whether the neuropathy is caused by the disease or by the chemotherapy used for the disease...
October 16, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28986470/quality-of-life-in-inflammatory-neuropathies-the-in-qol
#15
Thomas H P Draak, Catharina G Faber, Ingemar S J Merkies
BACKGROUND: No consensus exists which quality of life (QoL) measure should be used in patients with inflammatory neuropathies. Moreover, most QoL measures are ordinal-based scales with their known deficiencies. OBJECTIVES: To establish a new disease-specific interval-based QoL questionnaire in inflammatory neuropathies (IN-QoL) using the Rasch model and evaluate its scientific properties (validity, reliability and responsiveness). METHODS: 264 patients with inflammatory neuropathies completed six commonly used QoL questionnaires...
October 6, 2017: Journal of Neurology, Neurosurgery, and Psychiatry
https://www.readbyqxmd.com/read/28936613/chronic-inflammatory-demyelinating-polyradiculoneuropathy-and-anesthesia-a-case-series
#16
Andrew R Mortenson, Juraj Sprung, James C Watson, P James B Dyck, Toby N Weingarten
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an acquired autoimmune demyelinating polyneuropathy characterized by symmetrical diffuse weakness that also can rarely affect bulbar and respiratory muscles. The study objective was to describe perioperative outcomes of patients with CIDP who received general anesthesia. This retrospective observational study evaluated patients with active (diagnosed or treated within the previous year) CIDP who underwent general anesthesia at our institution between January 1, 2010, and December 31, 2015...
September 21, 2017: Acta Neurologica Belgica
https://www.readbyqxmd.com/read/28928949/plasmapheresis-in-neurological-disorders-six-years-experience-from-university-clinical-center-tuzla
#17
Osman Sinanović, Sanela Zukić, Adnan Burina, Nermina Pirić, Renata Hodžić, Mirza Atić, Mirna Alečković-Halilović, Enisa Mešić
BACKGROUND: Therapeutic plasma exchange (TPE) is an extracorporeal blood purification technique that is designed to remove substances with a large molecular weight. The TPE procedure includes removal of antibodies, alloantibodies, immune complexes, monoclonal protein, toxins or cytokines, and involves the replenishment of a specific plasma factor. The aim of the study was to describe the clinical response to TPE in various neurological patients, and to assess the clinical response to this therapy...
2017: F1000Research
https://www.readbyqxmd.com/read/28927011/assessing-autophagy-in-sciatic-nerves-of-a-rat-model-that-develops-inflammatory-autoimmune-peripheral-neuropathies
#18
REVIEW
Susana Brun, Nicolas Schall, Hélène Jeltsch-David, Jérôme de Sèze, Sylviane Muller
The rat sciatic nerve has attracted widespread attention as an excellent model system for studying autophagy alterations in peripheral neuropathies. In our laboratory, we have developed an original rat model, which we used currently in routine novel drug screening and to evaluate treatment strategies for chronic inflammatory demyelinating polyneuropathy (CIDP) and other closely related diseases. Lewis rats injected with the S-palmitoylated P0(180-199) peptide develop a chronic, sometimes relapsing-remitting type of disease...
September 18, 2017: Cells
https://www.readbyqxmd.com/read/28914883/cidp-and-other-inflammatory-neuropathies-in-diabetes-diagnosis-and-management
#19
REVIEW
Yusuf A Rajabally, Mark Stettner, Bernd C Kieseier, Hans-Peter Hartung, Rayaz A Malik
Distal symmetric polyneuropathy (DSPN) is the most common neuropathy to occur in diabetes mellitus. However, patients with diabetes can also develop inflammatory neuropathies, the most common and most treatable of which is chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Whether diabetes is a risk factor for CIDP remains under debate. Early studies suggested that patients with diabetes were at increased risk of CIDP, but epidemiological studies failed to confirm the association, and subsequent data have re-opened the debate...
October 2017: Nature Reviews. Neurology
https://www.readbyqxmd.com/read/28904461/the-prevalence-and-severity-of-autonomic-dysfunction-in-chronic-inflammatory-demyelinating-polyneuropathy
#20
Suresh Babu Pasangulapati, T V Murthy, Ajith Sivadasan, L Rynjah Gideon, A T Prabhakar, Aaron Sanjith, Vivek Mathew, Mathew Alexander
INTRODUCTION: In chronic inflammatory demyelinating polyneuropathy (CIDP), emphasis has been on motor disabilities, and autonomic dysfunction in these patients has not been addressed systematically. MATERIALS AND METHODS: Autonomic function was prospectively analyzed in 38 patients with CIDP. Quantitative autonomic function testing was done using Finometer(®) PRO and severity of adrenergic and cardiovagal dysfunction graded according to composite autonomic severity score and sudomotor dysfunction assessed using sympathetic skin response...
July 2017: Annals of Indian Academy of Neurology
keyword
keyword
8992
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"